Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:clofarabine
go back to main search page
Accession:CHEBI:681569 term browser browse the term
Definition:A purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia.
Synonyms:exact_synonym: 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine
 related_synonym: (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol;   2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine;   CAFdA;   Cl-F-Ara-A;   Formula=C10H11ClFN5O3;   InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1;   InChIKey=WDDPHFBMKLOVOX-AYQXTPAHSA-N;   SMILES=Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F;   clofarabina;   clofarabinum
 xref: Beilstein:4882539;   CAS:123318-82-1;   DrugBank:DB00631;   KEGG:D03546
 xref_mesh: MESH:C068329
 xref: PMID:19929004;   Wikipedia:Clofarabine



show annotations for term's descendants           Sort by:
 
clofarabine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Anp32b acidic nuclear phosphoprotein 32 family member B multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of ANP32B protein CTD PMID:20933509 NCBI chr 5:60,743,077...60,765,726
Ensembl chr 5:60,743,443...60,765,717
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of ATM protein CTD PMID:20933509 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [clofarabine co-treated with resveratrol] inhibits the reaction [BCL2L1 mutant form results in increased expression of MCL1 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP3 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP7 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased cleavage of CASP3 protein]; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP3 protein]; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP7 protein] CTD PMID:25408576 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of CASP3 protein; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP3 protein]; [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased cleavage of CASP3 protein]; [clofarabine co-treated with resveratrol] results in increased activity of CASP3 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]; [resveratrol co-treated with clofarabine] results in increased cleavage of and results in increased activity of CASP3 protein; [resveratrol co-treated with clofarabine] results in increased expression of CASP3 protein modified form; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] results in increased activity of CASP3 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of CASP3 protein] CTD PMID:20933509 PMID:24239893 PMID:24924397 PMID:25408576 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp7 caspase 7 multiple interactions ISO [clofarabine co-treated with resveratrol] promotes the reaction [BCL2L1 mutant form results in increased activity of CASP7 protein]; [clofarabine co-treated with resveratrol] results in increased activity of CASP7 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]; [resveratrol co-treated with clofarabine] results in increased activity of CASP7 protein; BCL2L1 protein affects the reaction [[clofarabine co-treated with resveratrol] results in increased activity of CASP7 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] results in increased activity of CASP7 protein] CTD PMID:24924397 PMID:25408576 NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of CASP9 protein CTD PMID:20933509 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [resveratrol co-treated with clofarabine] results in decreased expression of CCND1 protein CTD PMID:23146690 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cdc25b cell division cycle 25B multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CDC25B protein CTD PMID:20933509 NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[resveratrol co-treated with clofarabine] results in decreased expression of CDKN1A protein]; [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased expression of CDKN1A protein; [resveratrol co-treated with clofarabine] results in decreased expression of CDKN1A protein CTD PMID:20933509 PMID:23146690 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Chek1 checkpoint kinase 1 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CHEK1 protein CTD PMID:20933509 NCBI chr 8:36,420,565...36,443,477 JBrowse link
G Chek2 checkpoint kinase 2 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CHEK2 protein; [clofarabine co-treated with fludarabine] results in increased phosphorylation of CHEK2 protein CTD PMID:20933509 NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO [Clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased expression of H2AX protein CTD PMID:20933509 NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
decreases expression
ISO [clofarabine co-treated with resveratrol] inhibits the reaction [BCL2L1 mutant form results in increased expression of MCL1 protein]; [resveratrol co-treated with clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]; [resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]; [resveratrol co-treated with clofarabine] results in decreased expression of MCL1 protein; [resveratrol co-treated with clofarabine] results in increased expression of MCL1 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP3 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[resveratrol co-treated with clofarabine] promotes the reaction [MCL1 mutant form results in increased activity of CASP7 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[resveratrol co-treated with clofarabine] results in decreased expression of MCL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [clofarabine promotes the reaction [resveratrol results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol promotes the reaction [clofarabine results in decreased expression of MCL1 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[resveratrol co-treated with clofarabine] results in increased expression of MCL1 protein]; clofarabine promotes the reaction [resveratrol results in decreased expression of MCL1 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of CASP3 protein]; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein]; resveratrol promotes the reaction [clofarabine results in decreased expression of MCL1 protein] CTD PMID:24924397 PMID:25408576 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [resveratrol co-treated with clofarabine] results in decreased expression of MET protein CTD PMID:23146690 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in decreased expression of MYC protein CTD PMID:20933509 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of PARP1 protein; [resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein; [resveratrol co-treated with clofarabine] results in increased expression of PARP1 protein modified form; MCL1 mutant form promotes the reaction [[resveratrol co-treated with clofarabine] results in increased cleavage of PARP1 protein] CTD PMID:20933509 PMID:24239893 PMID:24924397 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Smc1a structural maintenance of chromosomes 1A multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of SMC1A protein CTD PMID:20933509 NCBI chr  X:21,103,323...21,148,053
Ensembl chr  X:21,103,282...21,148,056
JBrowse link
G Smc3 structural maintenance of chromosomes 3 multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of SMC3 protein CTD PMID:20933509 NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO [resveratrol co-treated with clofarabine] affects the localization of SP1 protein; [resveratrol co-treated with clofarabine] results in decreased expression of SP1 protein CTD PMID:23146690 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [resveratrol co-treated with clofarabine] affects the localization of TP53 protein modified form; [resveratrol co-treated with clofarabine] results in increased expression of and results in increased activity of TP53 protein modified form; TP53 protein affects the susceptibility to [resveratrol co-treated with clofarabine] CTD PMID:24239893 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO [clofarabine co-treated with fludarabine co-treated with Busulfan] results in decreased expression of XIAP protein CTD PMID:20933509 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19795
    role 19746
      biological role 19746
        biochemical role 19361
          antimetabolite 8545
            clofarabine 21
Path 2
Term Annotations click to browse term
  CHEBI ontology 19795
    subatomic particle 19794
      composite particle 19794
        hadron 19794
          baryon 19794
            nucleon 19794
              atomic nucleus 19794
                atom 19794
                  main group element atom 19693
                    p-block element atom 19693
                      carbon group element atom 19614
                        carbon atom 19604
                          organic molecular entity 19604
                            heteroorganic entity 19273
                              organochalcogen compound 19047
                                organooxygen compound 18993
                                  carbohydrates and carbohydrate derivatives 12344
                                    carbohydrate 12344
                                      carbohydrate derivative 11948
                                        glycosyl compound 10985
                                          N-glycosyl compound 5519
                                            nucleoside 5380
                                              ribonucleoside 684
                                                purine ribonucleoside 573
                                                  adenosines 557
                                                    clofarabine 21
paths to the root